Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR443579 + azacitidine + venetoclax
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
SAR443579 + azacitidine + venetoclax is an experimental three-drug combination regimen under investigation for the treatment of newly diagnosed, CD123-expressing acute myeloid leukemia (AML) in adults ineligible for intensive chemotherapy. **SAR443579** is a trifunctional natural killer cell engager (NKCE) designed to co-engage CD123 on tumor cells and the NK cell receptors NKp46 and CD16a, thereby forming a cytolytic synapse to activate NK cells and mediate targeted cell killing. **Azacitidine** is a hypomethylating agent (DNA methyltransferase inhibitor) that inhibits DNA methylation and induces cytotoxicity in abnormal hematopoietic cells. **Venetoclax** is a selective BCL-2 inhibitor that promotes apoptosis in cancer cells. The aim of combining these modalities is to increase anti-leukemic activity and overcome resistance mechanisms seen with venetoclax/azacitidine alone. This combination is currently in Phase 1/2 clinical trials sponsored by Sanofi, with SAR443579 being developed in partnership with Innate Pharma[1][3][5][6][7].
- Other names
- Venclexta + azacitidine + SAR443579
02
Targets
BCL-2 (BCL-2 family)DNMT (DNA methyltransferase)IL3RA (Interleukin 3 Receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)NCR1 (Natural cytotoxicity triggering receptor 1)
Beyond the preview
Go deeper on SAR443579 + azacitidine + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR443579 + azacitidine + venetoclax.